Cancer – ADVL1515: Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Condition or Therapy:
Solid tumors, CNS tumors, intrinsic brain stem tumors, optic pathway gliomas, pineal and elevations of CSF or serum tumor
Cancer and Bloor Disorders
Study Number: ADVL1515
What is the goal of this study?
This phase 1 trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are between 12 months and 21 years old
- Have a recurrent or refractory solid tumor
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.